Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Polhem Infra in conjunction with the signing of a framework agreement with Solkompaniet regarding solar power farms
Mandate

Vinge advises Polhem Infra in conjunction with the signing of a framework agreement with Solkompaniet regarding solar power farms

November 28, 2022 M&A Energy

Vinge has advised Polhem Infra in connection with the signing a framework agreement with Solkompaniet regarding projecting, development and the building of large scale solar power farms in Sweden.

The agreement enables the development and building of solar power farms with an estimated combined capacity of up to 600MW. The agreement includes two start-up projects under development by Solkompaniet with an estimated capacity of 100MW.

Vinge’s team consisted of  Henrik Ossborn, Christoffer Thalin and Carl Trolle Olson.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024